MEMPHASYS LIMITED. — Capital/Financing Update 2019

Feb 26, 2019

==> picture [221 x 65] intentionally omitted <==

ASX Announcement

27 February 2018

$3.64 million underwritten entitlement issue

Memphasys Limited (ASX: MEM) ( Memphasys or the Company ) is pleased to provide the following corporate update on its operations.

Entitlement Issue

The board of Memphasys has resolved to proceed with a non-renounceable pro-rata entitlement issue on the basis of one (1) share ( New Share ) for every two (2) shares held by eligible shareholders on the record date (expected to be on or about 7 March 2019). at an issue price of $0.02 per New Share.

The entitlement issue, to raise up to approximately $3.64 million (before costs) ( Offer ) is to be fully underwritten by Patersons Securities Limited.

The funds raised from the entitlement issue are to be used to further the development of the Felix device in preparation for commercialisation, working capital and repayment of Director loans.

New Shares issued under the Offer (totaling up to 182,044,573 shares) will be listed on the ASX and will rank pari-passu with existing fully paid ordinary shares.

Further information with respect to the Offer will be sent out in a Prospectus. The prospectus is intended to be lodged with the ASIC on or about 28 February 2019 and mailed to eligible shareholders shortly after the record date. Shareholders may view the Company’s ASX announcements, including those relating to the Offer, on the ASX website under the ASX code MEM.

Persons should consider the prospectus before deciding whether to acquire securities and eligible shareholders will need to complete the personalised entitlement and acceptance form that will accompany the prospectus in order to apply for New Shares under the Offer.

Dual listing on Frankfurt Stock Exchange

The Company is also pleased to announce that its shares are now quoted on the Frankfurt Stock Exchange (WKN: A2ANGR ISIN: AU000000MEM5). European investors are now able to trade the Company’s ordinary shares in Euros in their own time zone.

Ends

For further information please contact:

Investors	Media
Andrew Metcalfe	David Tasker/ Colin Jacoby
Company Secretary	Chapter One Advisors
T: +61 3 9867 7199	T: +61 433 112 936
E: andrew@accosec.com	E:dtasker@chapteroneadvisors.com.au
	Cjacoby@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company’s patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.

Website: http://www.memphasys.com.au